Abstract
Recent developments in 68Ga-radiopharmaceuticals, including a number of regulatory approvals for clinical use, has created a hitherto unprecedented demand for 68Ga. Reliable access to enough 68Ga to meet growing clinical demand using only 68Ge/68Ga generators has been problematic in recent years. To address this challenge, we have optimized the direct production of 68Ga on a cyclotron via the 68Zn(p,n)68Ga reaction using a liquid target. This protocol describes the cyclotron-based production of [68Ga]GaCl3 implemented at the University of Michigan using a liquid target on GE PETtrace instrumentation. The protocol provides 56 ± 4 mCi (n = 3) of [68Ga]GaCl3 that meets the necessary quality control criteria to use for the preparation of 68Ga-radiopharmaceuticals for human use.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Herrmann K, Schwaiger M, Lewis JS, Solomon SB, McNeil BJ, Baumann M, Gambhir SS, Hricak H, Weissleder R (2020) Radiotheranostics: a roadmap for future development. Lancet Oncol 21:e146–e156
Qaim SM, Scholten B, Neumaier B (2018) New developments in the production of theranostic pairs of radionuclides. J Radioanal Nucl Chem 318:1493–1509
Pencharz D, Gnanasegaran G, Navalkissoor S (2018) Theranostics in neuroendocrine tumours: somatostatin receptor imaging and therapy. Br J Radiol 91:20180108
FDA approves new diagnostic imaging agent to detect rare neuroendocrine tumors. [new release]. https://www.fda.gov/news-events/press-announcements/fda-approves-new-diagnostic-imaging-agent-detect-rare-neuroendocrine-tumors. Published 1 Jun 2016; Accessed 2 Jun 2021
Sunderland JJ (2020) The Academic NDA: justification, process, and lessons learned. J Nucl Med 61:480–487
RadioMedix and Curium Announce FDA Approval of Detectnet (copper Cu 64 dotatate injection) in the U.S. [news release]. https://www.curiumpharma.com/2020/09/08/radiomedix-and-curium-announce-fda-approval-of-detectnet-copper-cu-64-dotatate-injection-in-the-u-s/. Published 7-Sept-2020; Accessed 2 Jun 2021
Hennrich U, Kopka K (2019) Lutathera®: The first FDA- and EMA-approved radiopharmaceutical for peptide receptor radionuclide therapy. Pharmaceuticals (Basel) 12:114
Carlucci G, Ippisch R, Slavik R, Mishoe A, Blecha J, Zhu S (2021) 68Ga-PSMA-11 NDA approval: a novel and successful academic partnership. J Nucl Med 62:149–155
Wester HJ, Schottelius M (2019) PSMA-targeted radiopharmaceuticals for imaging and therapy. Semin Nucl Med 49:302–312
Kircher M, Herhaus P, Schottelius M, Buck AK, Werner RA, Wester HJ, Keller U, Lapa C (2018) CXCR4-directed theranostics in oncology and inflammation. Ann Nucl Med 32:503–511
Calais J (2020) FAP: the next billion dollar nuclear theranostics target? J Nucl Med 61:163–165
Fani M, André JP, Maecke HR (2008) 68Ga-PET: a powerful generator-based alternative to cyclotron-based PET radiopharmaceuticals. Contrast Media Mol Imaging 3:67–77
Cutler CS, Minoshima S. (2018) Shortage of Germanium68/gallium68 generators in the United States. https://s3.amazonaws.com/rdcms-snmmi/files/production/public/Ga68%20shortage%20letter.pdf. Accessed 1 Jun 2021
Rodnick ME, Sollert C, Stark D, Clark M, Katsifis A, Hockley BG, Parr DC, Frigell J, Henderson BD, Abghari-Gerst M, Piert MR, Fulham MJ, Eberl S, Gagnon K, Scott PJH (2020) Cyclotron-based production of 68Ga, [68Ga]GaCl3, and [68Ga]Ga-PSMA-11 from a liquid target. EJNMMI Radiopharm Chem 5:25
Alves F, Alves VHP, Do Carmo SJC, Neves ACB, Silva M, Abrunhosa AJ (2017) Production of copper-64 and gallium-68 with a 481 medical cyclotron using liquid targets. Mod Phys Lett A 32:1740013
Engle JW, Lopez-Rodriguez V, Gaspar-Carcamo RE, Valdovinos HF, Valle-Gonzalez M, Trejo-Ballado F et al (2012) Very high specific activity 66/68Ga from zinc targets for PET. Appl Radiat Isot 70:1792–1796
Graves SA, Engle JW, Eriksson TE, Gagnon K (2018) Dosimetry of cyclotron-produced [68Ga]Ga-PSMA-11, [68Ga]Ga-DOTA-TATE, and [68Ga]Ga-DOTA-TOC. J Nucl Med 59(Suppl. 1):1003
Jensen M, Clark JC. (2011) Direct production of Ga-68 from proton bombardment of concentrated aqueous solutions of [Zn-68] Zinc Chloride. In The 13th International Workshop on Targetry and Target Chemistry Proceedings by Horoun S, Givskov and Jensen M (Eds). Risø DTU, National Laboratory for Sustainable Energy, Technical University of Denmark. Roskilde. 288–292. Available online: https://inis.iaea.org/collection/NCLCollectionStore/_Public/43/006/43006750.pdf. Accessed 12 Aug 2020
Lin M, Waligorski GJ, Lepera CG (2018) Production of curie quantities of 68Ga with a medical cyclotron via the 68Zn(p,n)68Ga reaction. Appl Radiat Isot 133:1–3
Nair M, Happel S, Eriksson T, Pandey M, DeGrado T, Gagnon K (2017) Cyclotron production and automated new 2-column processing of [68Ga]GaCl3. Eur J Nucl Med Mol Imaging 44(Suppl 2):S119–S956
Pandey MK, Byrne JF, Jiang H, Packard AB, DeGrado TR (2014) Cyclotron production of 68Ga via the 68Zn(p,n) 68Ga reaction in aqueous solution. Am J Nucl Med Mol Imaging 4:303–310
Pandey MK, Byrne JF, Schlasner KN, Schmit NR, DeGrado TR (2019) Cyclotron production of 68Ga in a liquid target: Effects of solution composition and irradiation parameters. Nucl Med Biol 74/75:49–55
Riga S, Cicoria G, Pancaldi D, Zagni F, Vichi S, Dassenno M et al (2018) Production of Ga-68 with a General Electric PETtrace cyclotron by liquid target. Phys Med 55:116–126
Zeisler S, Limoges A, Kumlin J, Siikanen J, Hoehr C (2019) Fused zinc target for the production of gallium radioisotopes. Instruments 3:10
Sadeghi M, Kakavand T, Rajabifar S, Mokhtari L, Rahimi-Nezhad A (2009) Cyclotron production of 68Ga via proton-induced reaction on 68Zn target. Nukleonika 54:25–28
Gallium (68Ga) Chloride (accelerator produced) solution for radiolabelling. European Pharmacopoeia 2020;10(Suppl. 10.3):4864–4865
International Atomic Energy Agency (2019) Gallium-68 Cyclotron Production, IAEA-TECDOC-1863. IAEA, Vienna
New CRP: Production of Cyclotron-Based Gallium-68 Radioisotope and Related Radiopharmaceuticals (F22073). https://www.iaea.org/newscenter/news/new-crp-production-of-cyclotron-based-gallium-68-radioisotope-and-related-radiopharmaceuticals-f22073. Accessed 2 Jun 2021
Rinne SS, Abouzayed A, Gagnon K, Tolmachev V, Orlova A (2021) 66Ga-PET-imaging of GRPR-expression in prostate cancer: production and characterization of [66Ga]Ga-NOTA-PEG2-RM26. Sci Rep 11:3631
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2024 The Author(s), under exclusive license to Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Rodnick, M.E., Sollert, C., Parr, D.C., Frigell, J., Gagnon, K., Scott, P.J.H. (2024). Preparation of [68Ga]GaCl3 Using a Cyclotron. In: Witney, T.H., Shuhendler, A.J. (eds) Positron Emission Tomography. Methods in Molecular Biology, vol 2729. Humana, New York, NY. https://doi.org/10.1007/978-1-0716-3499-8_5
Download citation
DOI: https://doi.org/10.1007/978-1-0716-3499-8_5
Published:
Publisher Name: Humana, New York, NY
Print ISBN: 978-1-0716-3498-1
Online ISBN: 978-1-0716-3499-8
eBook Packages: Springer Protocols